Compare Pfizer Inc (PFE) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vale SA — how do they compare? Pfizer Inc trades at $24.9 (market cap $142.14B), while Vale SA trades at $14.87 (market cap $60.30B). The key difference: Pfizer Inc is far larger — about 2.4× Vale SA's market cap, and Vale SA pays the higher dividend (8.83%). Which is the better fit depends on your goals.
| PFE | VALE | |
|---|---|---|
Market Cap | $142.14B | $60.30B |
Volume | 29,869,932 | — |
Sector | Health | Basic Materials |
52-Week High | $28.56 | $17.82 |
52-Week Low | $23.29 | $9.53 |
Enterprise Value | $192.80B | $77.22B |
Dividend Yield | 6.9% | 8.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
VALE trades at $14.25, up 0.42% today but down 11% over the past month. Technical indicators show a bearish trend with moving averages signaling sell pressure. Fundamentally, revenue declined to $38.4B in 2025 with net income falling to $2.35B, though cash flow improved to $2.42B. Recent news highlights board governance disputes and a $2.6B decarbonization investment announced in June 2026.
The outlook remains cautious with mixed analyst ratings (40.5% buy, 48.7% hold) and a $17.13 consensus target. Risks include volatile iron ore prices and execution challenges, but stable cash flow and low debt provide some resilience. Upside depends on commodity demand recovery and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
